Mario Gabelli Incyte Corp Transaction History

Gamco Investors, Inc. Et Al

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $170,380 - $235,144	-2,800 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$83.06 - $100.98 $41,530 - $50,490	500 Added 21.74%	2,800 $233,000
Q4 2017 Feb 02, 2018	SELL	$93.56 - $116.6 $9,356 - $11,660	-100 Reduced 4.17%	2,300 $218,000
Q3 2017 Nov 01, 2017	BUY	$109.15 - $138.27 $261,960 - $331,848	2,400	2,400 $280,000

617

215M

366K

445K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.